Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Parker

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Asian Journal of Andrology|July 5, 2014
Reappraisal of glucocorticoids in castrate-resistant prostate cancerOliver Sartor, Christopher C Parker, Johann de Bono
Current Opinion in Supportive and Palliative Care|June 20, 2012
Use of radionuclides in metastatic prostate cancer: pain relief and beyondSalil Vengalil, Joe M O'Sullivan, Christopher C Parker
Current Opinion in Urology|October 5, 2019
Prostate radiotherapy in newly diagnosed metastatic prostate cancerAdnan Ali, Christopher C Parker, Noel W Clarke
BJU International|June 1, 2007
Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancerVedang Murthy, Andrew R Norman, Yolanda Barbachano, et al.
Nuclear Medicine Communications|December 1, 2017
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancerBrenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2019
Compartmental Model for <sup>223</sup>Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate CancerJan Taprogge, Iain Murray, Jonathan Gear, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 2, 2010
Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillanceRamachandran Venkitaraman, Karen Thomas, Phillip Grace, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Technological advances in radiotherapy for the treatment of localised prostate cancerStephen A Mangar, Robert A Huddart, Christopher C Parker, et al.
The New Phytologist|September 7, 2016
PCP-B class pollen coat proteins are key regulators of the hydration checkpoint in Arabidopsis thaliana pollen-stigma interactionsLudi Wang, Lisa A Clarke, Russell J Eason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2015
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal MetastasesSarah J Chittenden, Cecilia Hindorf, Christopher C Parker, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Asian Journal of Andrology|July 5, 2014
Reappraisal of glucocorticoids in castrate-resistant prostate cancerOliver Sartor, Christopher C Parker, Johann de Bono
Current Opinion in Supportive and Palliative Care|June 20, 2012
Use of radionuclides in metastatic prostate cancer: pain relief and beyondSalil Vengalil, Joe M O'Sullivan, Christopher C Parker
Current Opinion in Urology|October 5, 2019
Prostate radiotherapy in newly diagnosed metastatic prostate cancerAdnan Ali, Christopher C Parker, Noel W Clarke
BJU International|June 1, 2007
Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancerVedang Murthy, Andrew R Norman, Yolanda Barbachano, et al.
Nuclear Medicine Communications|December 1, 2017
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancerBrenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2019
Compartmental Model for <sup>223</sup>Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate CancerJan Taprogge, Iain Murray, Jonathan Gear, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 2, 2010
Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillanceRamachandran Venkitaraman, Karen Thomas, Phillip Grace, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2005
Technological advances in radiotherapy for the treatment of localised prostate cancerStephen A Mangar, Robert A Huddart, Christopher C Parker, et al.
The New Phytologist|September 7, 2016
PCP-B class pollen coat proteins are key regulators of the hydration checkpoint in Arabidopsis thaliana pollen-stigma interactionsLudi Wang, Lisa A Clarke, Russell J Eason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2015
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal MetastasesSarah J Chittenden, Cecilia Hindorf, Christopher C Parker, et al.
Pageof 6